No Data
No Data
No Data
No Data
No Data
ITeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity From Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984
Globe NewswireApr 8 04:30
Analysts Offer Insights on Healthcare Companies: ITeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)
TipRanksMar 21 19:30
Top Premarket Decliners
SurgePays (SURG) shares slumped 22% Wednesday premarket after the company reported lower Q4 revenue. Latham Group (SWIM) shares dropped 18% after the company reported lower Q4 sales. Bit Origin (BTOG)
MT NewswiresMar 13 20:03
ITeos Therapeutics Is Maintained at Overweight by JP Morgan
ITeos Therapeutics Is Maintained at Overweight by JP Morgan
Dow JonesMar 12 21:20
JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $27
JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from $29 to $27.
BenzingaMar 12 21:09
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and ITeos Therapeutics (ITOS)
TipRanksMar 12 18:40
No Data
No Data